ILD/DPLD of known origin最新文献_第8页

Interstitial Pneumonia with Autoimmune Features (IPAF): a single center prospective experience 具有自身免疫特征的间质性肺炎(IPAF):一项单中心前瞻性研究

ILD/DPLD of known origin Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.PA2968

G. Sambataro, S. Torrisi, A. Vancheri, M. Pavone, Roberta Rosso, Matteo Schisano, C. Crimi, D. Sambataro, C. Vancheri

{"title":"Interstitial Pneumonia with Autoimmune Features (IPAF): a single center prospective experience","authors":"G. Sambataro, S. Torrisi, A. Vancheri, M. Pavone, Roberta Rosso, Matteo Schisano, C. Crimi, D. Sambataro, C. Vancheri","doi":"10.1183/13993003.CONGRESS-2018.PA2968","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA2968","url":null,"abstract":"Introduction: The term Interstitial Pneumonia with Autoimmune Features (IPAF) has been proposed to classify patients with Interstitial Lung Disease (ILD) associated with autoimmune signs not classifiable for a specific Connective Tissue Disease (CTD). Currently, no prospective IPAF cohort are reported. Aims and Objectives: To describe a prospective cohort of IPAF patients. Methods: The study was conducted according to the declaration of Helsinki. A total of 170 consecutive ILD patients with at least one IPAF criteria were considered in the last year (Fischer A, Eur Respir J 2015; 46 (4): 976-987). From these, 58 patients were able to satisfy classification criteria for CTDs, while 33 patients were classified as IPAF. Results: IPAF patients (69.7% females) referred a history of smoke in 51.5% of cases and reported a restrictive pattern in Pulmonary Function Tests in 66.7% of cases. A clinical domain was present in 72.7% of patients, whereas serological and morphological domains respectively in 72.7% and 87.9% of cases. The most frequent item from each domain were arthritis (42.4%), Antinuclear Antibodies (ANA) (30.3%) and Nonspecific Interstitial Pneumonia (75.8%) as HRCT pattern. No cases of ulcers, telangiectasia and mechanic’s hand were reported. Only ANA, Rheumatoid Factor, anti-SSA, anti DsDNA and Anti Citrullinated Protein Antibodies were found as serological domain. Conclusions: This study suggests that most of IPAF patients have a clinically relevant ILD without serological and clinical items highly specific for CTDs. When these items were present, patients were generally able to satisfy specific CTD criteria. Probably, some of IPAF patients can have an early form of CTDs.","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128054619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Positive correlation between sympathetic modulation and peace in patients with interstitial lung disease 肺间质性疾病患者交感调节与安宁的正相关

ILD/DPLD of known origin Pub Date : 2018-09-15 DOI: 10.1183/13993003.congress-2018.pa2985

Katya Rigatto, Ana Amélia Machado Duarte, C. Mostarda, G. Watte, G. Lucchetti, P. J. Z. Teixeira

引用次数: 0

Non Specific Interstitial Pneumonia and features of connective tissue disease:what are the consequences of a different point of view? 非特异性间质性肺炎与结缔组织病的特征:不同观点的后果是什么?

ILD/DPLD of known origin Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.PA2972

Alice Biffi, G. Dei, Anna Stainer, F. D. Giacomi, M. Pozzi, P. Faverio, A. Pesci

引用次数: 3

Prognostic impact of bronchoalveolar lavage lymphocytosis in patients with chronic Hypersensitivity Pneumonitis 支气管肺泡灌洗淋巴细胞增多症对慢性超敏性肺炎患者预后的影响

ILD/DPLD of known origin Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.OA3817

J. Wälscher, B. Gross, J. Bruhwyler, J. Morisset, C. Heussel, F. Lasitschka, F. Herth, M. Kreuter

引用次数: 4

Late Breaking Abstract - Clinical utility of basophil activating test (BAT) in subjects with drug-induced lung disease. 摘要-嗜碱性粒细胞激活试验(BAT)在药物性肺部疾病患者中的临床应用。

ILD/DPLD of known origin Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.OA3815

S. Suzuki, T. Homma, S. Ohta, K. Fujiwara, Y. Miyata, Y. Kishino, A. Tanaka, T. Ohnishi, H. Sagara

引用次数: 0

Pirfenidone as a treatment for asbestos-related lung fibrosis? A retrospective case series 吡非尼酮治疗石棉相关肺纤维化?回顾性病例系列

ILD/DPLD of known origin Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.PA2993

F. Rytz, A. Poellinger, S. Berezowska, T. Geiser, M. Funke-Chambour

{"title":"Pirfenidone as a treatment for asbestos-related lung fibrosis? A retrospective case series","authors":"F. Rytz, A. Poellinger, S. Berezowska, T. Geiser, M. Funke-Chambour","doi":"10.1183/13993003.CONGRESS-2018.PA2993","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA2993","url":null,"abstract":"Pirfenidone is an established treatment for idiopathic pulmonary fibrosis (IPF). The efficacy in other fibrotic lung diseases has not been tested so far. Asbestos-related lung disease can manifest with inflammation and progressive lung fibrosis with currently no approved treatment option. Pirfenidone with its anti-inflammatory and antifibrotic effects might represent a possible drug treatment. As differentiating between IPF and asbestos-related disease is difficult, patients with a UIP-pattern and signs of asbestos-related disease were retrospectively analyzed within the idiopathic interstitial pneumonia-cohort study. Signs for asbestos-related disease included significant exposure in all patients, pleural plaques in 3/4 patients, presence of asbestos fibres in bronchoalveolar lavage or tissue in 2/4 patients. All 4 patients showed progressive fibrosis within 6 months prior to treatment with a mean decline in forced vital capacity (FVC) of 325 +/- 200 ml. They were subsequently treated with Pirfenidone (3x801mg/day). All patients showed stabilization or even improvement of FVC after 3-6 months of Pirfenidone treatment. Increase of FVC after 6 months was in average +173 +/- 220ml. Side effects were comparable to observed side effects in IPF (nausea, weight loss, phototoxicity) and led to dose reduction in 2 patients (3x534mg/day). In conclusion, this retrospective case series suggest that treatment with Pirfenidone in patients with possible asbestos-related progressive lung fibrosis is well tolerated and resulted in stabilization or even improvement of FVC. Nevertheless, these retrospective findings require confirmation in randomized, placebo-controlled prospective trials.","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"90 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129447882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systematic review: In vivo imaging in animal models relevant to drug-induced Interstitial lung disease (DIILD) 系统综述:与药物性间质性肺疾病(DIILD)相关的动物模型的体内成像

ILD/DPLD of known origin Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.PA2956

I. M. Persson, K. Wachenfeldt, Kashmira Pindoria, Juan A. Delgado-San Martin, S. Campbell, Michael V. Haase, Mark Wright, J. Waterton, L. Olsson

引用次数: 1

Physical and biochemical interactions drive fibrocytes accumulation in the scleroderma lung matrix 物理和生化相互作用驱动硬皮病肺基质中纤维细胞的积累

ILD/DPLD of known origin Pub Date : 2018-09-15 DOI: 10.1183/13993003.congress-2018.lsc-1176

Huanxing Sun, J. Winkler, M. Minasyan, Hongyi Pan, O. Desai, A. Pellowe, J. Li, X. Peng, Anjelica L Gonzalez, E. Herzog

引用次数: 0

A case series study on re-treatment to lung cancer after drug-induced interstitial lung disease 药物性间质性肺疾病后再治疗肺癌的病例系列研究

ILD/DPLD of known origin Pub Date : 2018-09-15 DOI: 10.1183/13993003.congress-2018.pa3668

S. Terada, T. Hajiro, Hidetaka Yutani, Masakuni Ueyama, T. Nakanishi, Nobuyoshi Hamao, T. Inao, Yusuke Kaji, Takehiro Yasuda, S. Hashimoto, E. Tanaka, Y. Taguchi

引用次数: 1

Quality of life of the patients followed for diffuse interstitial pneumonitis with fibrosis 观察弥漫性间质性肺炎伴纤维化患者的生活质量

ILD/DPLD of known origin Pub Date : 2018-09-15 DOI: 10.1183/13993003.congress-2018.pa3670

Elhamdaoui Lamyae, J. Hasna, Elkhattabi Wiam, Afif Hicham

引用次数: 0